<DOC>
	<DOCNO>NCT03011463</DOCNO>
	<brief_summary>The purpose study : - determine absolute bioavailability , input rate , distribution volume , renal intestinal excretion trospium subject wild-type SLC22A1 rs72552763 rs12208357 subject homozygous variant allele SLC22A1 rs72552763 rs12208357 - determine absolute bioavailability , input rate , distribution volume renal intestinal excretion trospium subject wild-type allele SLC22A1 rs72552763 rs12208357 co-medication 300 mg OCT1- inhibitor ranitidine - determine absolute bioavailability , input rate , distribution volume renal intestinal excretion trospium subject wild-type allele SLC22A1 rs72552763 rs12208357 co-medication 500 mg P-glycoprotein- inhibitor clarithromycin - determine absolute bioavailability , input rate , distribution volume renal intestinal excretion trospium subject homozygous variant allele SLC22A1 rs72552763 rs12208357 co-medication 500 mg P-glycoprotein- inhibitor clarithromycin .</brief_summary>
	<brief_title>Pharmacokinetic Interaction Between Trospium With Inhibitor OCT1 P-gp Subjects Genotyped OCT1</brief_title>
	<detailed_description />
	<mesh_term>Trospium chloride</mesh_term>
	<mesh_term>Ranitidine</mesh_term>
	<mesh_term>Ranitidine bismuth citrate</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>ethnic origin : Caucasian genotype OCT1 : wildtype homozygous variant allele SLC22A1 rs72552763 rs12208357 . body mass index : ≥ 18.5 kg/m² ≤ 30 kg/m² good health evidence result clinical examination , ECG , laboratory checkup , judge clinical investigator differ clinical relevant way normal state ( blood pressure 110/70 140/90 male 100/60 140/90 female , heart rate 50 bpm 90 bpm , laboratory value within reference range give actually laboratory stored TMF ) write informed consent hepatic renal disease and/or pathological finding , might interfere pharmacokinetics pharmacodynamics study medication ( e.g . hepatic renal dysfunction , obstruction urine flow urinary retention subvesical obstruction like benign prostatic hyperplasia , infection tumor urinary tract ) organic cause polydipsia pollakiuria exist cardiac hematological disease and/or pathological finding , might interfere drug 's safety , tolerability and/or pharmacokinetics ( e.g . tachycardia , tachyarrhythmia , bradycardia , heart failure , coronary heart disease , disturbance stimulus conduction ) pneumonia pharyngitis acute phorphyria hyperthyroidism galactoseintolerance , lactase deficiency glucosegalactose malabsorption electrolyte disturbance gastrointestinal disease and/or pathological finding ( e.g . hiatus hernia gastroesophageal reflux , stenosis , ulcera , severe chronic inflammatory bowel disease like ulcerative colitis Crohn 's disease , toxic megacolon ) , might interfere pharmacokinetics pharmacodynamics study medication ) autonomic neuropathy myasthenia gravis narrowangle glaucoma drug alcohol dependence positive drug alcohol screen smoker 10 cigarette per day positive result HIV , HBV HCV screening subject diet could affect pharmacokinetics drug ( e. g. vegan , vegetarian ) heavy tea coffee drinker ( 1L per day ) lactation , pregnancy test positive perform woman childbearing age without safe contraception state Note Guidance Nonclinical Safety Studies Conduct Human Clinical Trials Pharmaceutical ( CPMP/ICH/286/95 modification : implant , injectables , combine oral contraceptive , IUDs , sexual abstinence vasectomise partner barriermethods combination one aforementioned ) subject suspect know follow instruction clinical investigator subject unable understand write verbal instruction , particular regard risk inconvenience expose result participation study subject liable orthostatic dysregulation , fainting , blackouts participation clinical trial last 3 month prior start study le 14 day last acute disease le 3 month last blood donation medication within 4 week prior intend first administration study medication might influence function gastrointestinal tract ( e.g . laxative , metoclopramide , loperamide , antacid , H2receptor antagonists , proton pump inhibitor , anticholinergic ) medication within two week prior first administration study medication , least 10time halflive respective drug ( except oral contraceptive ) intake grapefruit orange contain food beverage within 14 day prior administration study medication intake poppy seed contain food beverage within 14 day prior administration study medication know allergic reaction active ingredient use , H2receptor antagonists , macrolide antibiotic constituent study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>